Canadian Journal of Cardiology

Response to Dr. Du letter to the editor

Published:September 21, 2022DOI:
      Thank you Dr. Du for the commentary regarding our manuscript: The effectiveness of sodiumglucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis. The differential effectiveness of the two classes regarding the aforementioned critical endpoints was highlighted in the review's results and discussion sections. In addition, distinctions were made on a clinical basis in the guideline (published in parallel) and specifically concerning the absence of dedicated trials for GLP-1RA in patients with HF or CKD. We do emphasize, with prominence, the issue of stroke reduction with GLP-1RA as well.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Linked Article

      • Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke
        Canadian Journal of Cardiology
        • Preview
          Ali et al.1 conducted a wonderful and comprehensive meta-analysis1 based on all the available cardiovascular outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is; 11 CVOTs) and glucagon-like peptide 1 receptor agonists (GLP1RAs; 8 CVOTs), drawing their main conclusion that both SGLT2is and GLP1RAs yielded the statistically significant benefits across most cardiorenal end points in the populations studied. This conclusion only emphasises the similarity between GLP1RAs and SGLT2is in cardiorenal benefits, but ignores the differences between them in specific cardiorenal outcomes.
        • Full-Text
        • PDF